Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2022

View Archived Issues

Study shows disease-linked DNA variants are active at different stages of T-cell activation

Pendrin inhibitor ARBM-201 reduces lung injury in acute respiratory distress syndrome model

NLRP3 inflammasome inhibitor INF-176 for the treatment of Alzheimer's disease

MAb-loaded extracellular vesicles show potential as cancer therapeutics

Shanghai Yao Biotech discloses new TRK inhibitors

Sichuan Haisco Pharmaceutical patents ENPP2 inhibitors

Tyligand Bioscience divulges GTPase KRAS mutant inhibitors

Betta Pharmaceuticals identifies new IDH inhibitors

Broadenbio synthesizes new MAP4K1 inhibitors

Morc2 S87L mutation in mice mimics human Charcot-Marie-Tooth disease

TrxR inhibitor Au-24 shows promise in vivo and in vitro for treating hepatocellular carcinoma

Atux Iskay presents preclinical data on PP2A activator ATUX-792 in IPF

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 6, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...